Filing summary
Issuer and period: The supplied filing is Sunshine Heart, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 15, 2016. The request identifies Nuwellis, Inc.; the issuer-name difference should be verified. The filing also provides unaudited fourth-quarter data.
Business context and reporting period
Sunshine Heart was an early-stage medical-device company developing the C-Pulse Heart Assist System for moderate-to-severe heart failure. The device was not approved for commercial sale in the United States; revenue came from limited clinical-study placements. The company reported 2015 results and comparative figures for 2014 and 2013.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $59,000 | $295,000 |
| Operating expenses | $26.017 million | $26.082 million |
| Operating loss | $25.958 million | $25.787 million |
| Net loss | $26.583 million | $25.587 million |
| Basic and diluted loss per share | $1.47 | $1.51 |
| Cash used in operating activities | $22.989 million | $22.644 million |
| Cash and cash equivalents at year-end | $23.113 million | $31.293 million |
| Working capital at year-end | $15.594 million | $28.554 million |
| Debt outstanding, principal | $8.0 million | None reported |
FY 2015 investing cash outflow was $0.199 million; financing provided $15.055 million, including $8.0 million of borrowings and net equity proceeds. Cash declined by $8.180 million. Gross margin was not separately reported; clinical-study product costs were expensed as research and development. At year-end, total assets were $24.570 million and total liabilities were $12.399 million.
Fourth quarter: 2015 revenue was zero, operating expenses were $6.354 million, net loss was $6.604 million and loss per share was $0.36. In Q4 2014, revenue was $177,000, operating expenses were $6.833 million, net loss was $6.743 million and loss per share was $0.40.
Material changes versus prior periods
- FY 2015 revenue fell 80% from 2014, reflecting one revenue-generating implant versus five in 2014.
- Net loss increased by about $1.0 million year over year. R&D expense rose 4.7% to $17.672 million, while selling, general and administrative expense declined 9.4% to $8.345 million.
- Other expense increased to $749,000, primarily from interest on the new Silicon Valley Bank loan. Cash fell by $8.180 million, while debt rose to $8.0 million.
Outlook, risks and unusual items
- On March 3, 2016, after year-end, the company announced it had stopped enrolling patients in the COUNTER HF and OPTIONS HF studies. It planned to pursue a shorter clinical study, improve the current device and procedure, and accelerate development of a fully implantable system. These plans remained subject to regulatory discussions and approvals.
- Management expected no clinical-study revenue in 2016 and significant losses to continue. It expected cash to fund operations into the second half of 2016 and planned to seek additional financing during that period; availability and terms were uncertain.
- The auditor’s report and management’s disclosure raised substantial doubt about the company’s ability to continue as a going concern. The statements contain no adjustments that might be required if it could not continue as a going concern.
- The $8.0 million Silicon Valley Bank loan carried a 7% interest rate, was due in December 2017, and required principal repayment in 24 monthly installments beginning January 2016, plus a final payment equal to 5% of original principal. The loan was secured by company assets and included a liquidity covenant; the company reported covenant compliance at year-end.
- Clinical feasibility results showed improvements in several measures, but came from a small patient cohort. The filing reports device-related serious adverse events, including one aortic disruption and eight drive-line exit-site or pocket infections among 21 subjects.
- Key risks include dependence on one development-stage product, lack of U.S. marketing approval, uncertain reimbursement and clinical success, financing needs, and reliance on a single supplier for the specialized balloon component.
Important facts for investors to verify
- Confirm whether this Sunshine Heart filing is the intended filing for Nuwellis, Inc.
- Review subsequent financing, cash runway, debt repayments and compliance with the loan’s liquidity covenant.
- Check the status, design, cost and FDA pathway for the proposed replacement clinical study and fully implantable device.
- Verify whether clinical findings and adverse-event disclosures have been updated with further patient follow-up or study analyses.
- Assess dilution potential: the company had an at-the-market equity program with $32.6 million available for future sales as of March 14, 2016.